Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has no to few central effects. A synthetic quaternary amine, it is available in oral and intravenous forms and as inhalation. It was developed by Sosei and licensed to Novartis in 2005. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN).
Mechanism of action
Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Like other anticholinergic (antimuscarinic) agents, it inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.
- Airway Obstruction
- Chronic Obstructive Pulmonary Disease (COPD)
- Hypersecretion gastric
- Increased bronchial secretion
- Muscarinic effects caused by neostigmine
- Muscarinic effects caused by pyridostigmine
- Neurocardiogenic Syncope
- Peptic Ulcers
- Salivary hypersecretion
- Chronic, severe Salivary hypersecretion
- Pharyngeal secretions
##Details coming soon